Search | Clinical Trials Finder

Conditions: Hypermobile Ehlers-Danlos Syndrome, Heavy Menstrual Bleeding, Hypermobility Syndrome (Disorder)
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 12 Years to 40 Years · Female only
Enrollment: 15 participants
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Heavy Menstrual Bleeding
Interventions: Web-based data collection, Paper-based data collection; Other
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years to 51 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Heavy Menstrual Bleeding, Uterine Fibroids
Interventions: Elagolix, Estradiol /norethindrone acetate (E2/NETA), E2/NETA Placebo, Elagolix Placebo; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 155
States / cities: Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 112 more

Conditions: Estrogen Deficiency, Cardiovascular Disease (CVD), Functional Hypothalamic Amenorrhea, Endothelial Dysfunction
Interventions: 17beta Estradiol, Transdermal placebo patch, Progesterone, Placebo Pill; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Uterine Fibroid, Endometriosis
Interventions: Not listed
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 660 participants
Timeline: 2018 – 2020
U.S. locations: 37
States / cities: Mobile, Alabama • Mesa, Arizona • Huntington Beach, California + 31 more

Conditions: Anovulation, Amenorrhea, Infertility, Starvation
Interventions: Energy availability; Behavioral
Lead sponsor: Ohio University; Other
Eligibility: 18 Years to 34 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Athens, Ohio

Conditions: Menorrhagia
Interventions: Levonorgestrel IUS (Mirena, BAY86-5028), Medroxyprogesterone acetate; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 37
States / cities: Tucson, Arizona • Beverly Hills, California • Carmichael, California + 32 more

Conditions: Menstruation Disturbances
Interventions: micronized progesterone, transdermal estradiol; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 12 Years to 16 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Heavy Menstrual Bleeding
Interventions: Juveena Hydrogel System; Device
Lead sponsor: Rejoni Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Little Rock, Arkansas • West Orange, New Jersey • Cincinnati, Ohio

Conditions: Heavy Menstrual Bleeding, Bleeding Disorder, Von Willebrand Diseases
Interventions: Levonorgestrel Intrauterine System, Norethindrone Acetate; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 10 Years to 24 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 9
States / cities: Palo Alto, California • Aurora, Colorado • Atlanta, Georgia + 5 more

Conditions: PMS, Menstrual Pain
Interventions: Elix Cycle Balance; Dietary Supplement
Lead sponsor: Zenchi, Inc.; Industry
Eligibility: 18 Years to 36 Years · Female only
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: PMS
Interventions: escitalopram, placebo; Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 15 Years to 19 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Menstrual Regulation, Menstrual Irregularity
Interventions: Misoprostol; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Fresno, California

Conditions: Menstrual Cramps, Women's Health, Fatigue
Interventions: My Happy Flo; Dietary Supplement
Lead sponsor: My Happy Flo; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Menorrhagia, Heavy Menstrual Bleeding
Interventions: Tranexamic acid tablets, Placebo tablets; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 83
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 76 more

Conditions: Infertility, Menorrhagia
Interventions: Salpingography; Procedure
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 621 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Menorrhagia
Interventions: Aurora Endometrial Ablation, Rollerball Ablation/Resection; Device
Lead sponsor: Minerva Surgical, Inc.; Industry
Eligibility: 25 Years to 50 Years · Female only
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 8
States / cities: Chandler, Arizona • Phoenix, Arizona • Newburgh, Indiana + 5 more

Conditions: Menstruation Disorders, Menstrual Cramps, Menstruation
Interventions: Seed Cycling; Dietary Supplement
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Leiomyoma, Uterine Fibroids, Uterine Neoplasms, Menorrhagia, Leiomyomatosis
Interventions: Uterine Fibroid Embolization (UFE), Contour SE™ Microspheres, Embosphere® Microspheres; Procedure · Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Heavy Menstrual Bleeding
Interventions: Sparrow Link, Sparrow Link (Sham); Device
Lead sponsor: Spark Biomedical, Inc.; Industry
Eligibility: 14 Years to 45 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metrorrhagia, Pelvic Pain, Menorrhagia, Leiomyoma
Interventions: Myfembree Oral Product; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: Chicago, Illinois • Flossmoor, Illinois • Orland Park, Illinois + 1 more

Conditions: Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 14 Years to 25 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Uterine Fibroids, Heavy Menstrual Bleeding
Interventions: OBE2109, Placebo to match OBE2109, Placebo to match Add-back, Add-back; Drug
Lead sponsor: ObsEva SA; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 23
States / cities: Chino, California • Huntington Park, California • San Diego, California + 19 more

Conditions: Von Willebrand Disease, Type 1, Heavy Menstrual Bleeding
Interventions: Volta System; Device
Lead sponsor: Five Liters, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Identifying the Determinants of Bleeding and Hypermobility in Patients With Heavy Menstrual Bleeding

HMB- Data Collection Methods

Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women

Bone Mineral Density in Women With Uterine Fibroids or Endometriosis

Effects of Gynecological Age on LH Sensitivity to Energy Availability

Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)

Investigation of Female Reproductive Hormone Dynamics During Adolescence

Juveena Hydrogel System Feasibility Study for Heavy Menstrual Bleeding (HMB)

Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study

Study to Evaluate the Efficacy of Elix's Cycle Balance and Its Impact on PMS and Menstrual Symptoms

Escitalopram for Premenstrual Syndrome (PMS) in Teens: A Pilot Study

Missed Period Pill Study

A Study to Assess the Effect of My Happy Flo on Alleviating Period Symptoms and Heavy Flows.

Efficacy and Safety of XP12B in Women With Menorrhagia

Hysteroscopic Assessment of Fallopian Tubal Patency

Minerva Pivotal Study to Evaluate Safety and Efficacy of the Aurora Endometrial Ablation System Compared to Hysteroscopic Rollerball Ablation

Impact of Seed Cycling on Menstrual Regularity, Dysmenorrhea, and Premenstrual Symptoms

A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE)

Delivering tAN to Reduce HMB: The LUNA Study

Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL)

NAFLD in Adolescents and Young Adults With PCOS

Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Delivering Transcutaneous Auricular Neurostimulation to Reduce Heavy Menstrual Bleeding in Patients With and Without Von Willebrand Disease